Sixtyfour CEO Saarth Shah explains how his company built AI research agents around rigorous evaluation systems rather than language model fluency, creating verification infrastructure that proves ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

On July 4, 2026, Vitalik Buterin published the most consequential Ethereum protocol document in four years: an updated "Lean Ethereum" strawmap that commits the world's second-largest blockchain to ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At present data scientists work on the theory of AI and coders put it into ...

Treat an LLM as the step function of a Turing machine. Everything else falls out: state lives on disk, the program is markdown, runs are resumable and observable, and "agents" are just user-authored ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

Microsoft on Monday unveiled the Surface RTX Spark Dev Box, a compact desktop computer designed to let software developers run large AI models on their desks instead of paying for cloud computing — a ...

Abstract: JavaScript has significantly evolved, broadening its capabilities. However, the uptake of tail call optimization (TCO) remains limited, largely due to concerns about debugging difficulties ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...